FMS - DaVita down 18% as credit swaps rise on Ozempic kidney failure study
2023-10-11 14:51:11 ET
More on DaVita
- DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
-
DaVita stock sell-off over Ozempic study 'big overreaction,' says UBS
-
DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold
- Biggest stock movers today: Pioneer Natural Resources, Exxon Mobil, Plug Power and more
- DaVita stock sell-off over Ozempic study 'big overreaction,' says UBS
For further details see:
DaVita down 18% as credit swaps rise on Ozempic kidney failure study